Discrimination Took A Toll on the Mental Health of Racial and Ethnic Minority Groups During the COVID-19 Pandemic
The pandemic was a particularly stressful period for communities that have faced discrimination in this country.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Contact Information
Jackson Building, 1st floor
55 Fruit Street
Boston,
MA
02114
Phone: 617-724-5510
Fax: 617-643-9048
Appointments
Ketamine IV appointments are conducted in the Intravenous Ketamine Clinic on the Mass General main campus on Tuesday and Thursday evenings from 5:30 pm-8:30 pm.
Referrals
Referring clinicians should fill out the referral form so we can determine whether the program is a good fit for the individual and gather relevant clinical information. A completed referral form is required prior to treatment.
Please send completed referral forms to mghketamineclinic@mgh.harvard.edu.
The Intravenous Ketamine Clinic for Depression at Massachusetts General Hospital combines advanced psychopharmacology expertise with knowledge stemming from a decade of ketamine research. We offer treatment for patients with severe and refractory depression using the medication ketamine given through intravenous infusion or through the nose (intranasal). We work collaboratively with the outpatient treatment team to develop an appropriate plan for each patient.
As a part of the Depression Clinical and Research Program at Mass General, we are committed to advancing our knowledge and ability to treat depression by integrating clinical care and innovative research. We do this through a number of avenues:
After a thorough consultation process, we offer IV infusions and intranasal ketamine maintenance to patients with severe depression or chronic suicidal ideation.
Ketamine treatment may be covered by your insurance, but to be sure please contact your insurer for updated information. The coverage of ketamine treatments is rapidly evolving at this time.
For 80 years, Mass General's Psychiatry Department has provided the highest quality patient care through pioneering research.
We provide care for patients of any age throughout the lifespan.
The pandemic was a particularly stressful period for communities that have faced discrimination in this country.
Mass General researchers are testing how medical marijuana usage impacts mental health outcomes.
Mass General researchers are testing the psychedelic compound psilocybin as a therapeutic for treatment-resistant depression.
TEMPOS is a user-friendly rating scale that can be used to assess adherence to reporting recommendations.
The hype over medical marijuana for treating health problems may be exaggerated, researchers find.
Teens who have frequent suicidal thoughts are at risk for a variety of psychological and social problems, according to a new study by researchers at Massachusetts General Hospital (MGH).
The integration of patient care and clinical research has been a hallmark of the Department of Psychiatry for more than 30 years. Today, the department has the largest clinical research program in the hospital, with studies at the forefront of neuroscience, molecular biology and genetics.